EpiBiome is a venture-backed precision microbiome engineering company with the mission of developing effective and sustainable FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of small-molecule antibiotics. Its first product will address bovine mastitis, an inflammation of the udder tissue in dairy cows, usually caused by bacterial infection. Bovine mastitis results in $35 billion and $2 billion in losses to the global and US dairy industries, respectively, due to reduced milk production and milk quality.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/04/16 | $6,000,000 | Series A |
Alexandria Venture Investments China Rock Capital Illumina For Startups Matrix Capital Management SV Tech Ventures | undisclosed |
